Pfizer said in a Dec. 12 news release that it is donating the rights to address concerns from antitrust regulators related to its $43 billion deal to buy Seagen. The drugmaker received the required regulatory approvals and expects to close the deal on Dec. 14 after announcing the deal in March.
After the deal closes, Pfizer said it will create a separate cancer drugs operation led by Chris Boshoff, MD, PhD, who will serve as chief oncology officer and executive vice president. The new structure and rights agreement will go into effect January 1.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.